Third Quarter Conference Calls, In Brief
Pfizer Spiriva production: Boehringer-Ingelheim "has sufficient manufacturing capacity already in Germany" to meet demand for the chronic obstructive pulmonary drug Spiriva (tiotropium) "for out as far as we can see," Pfizer CEO Henry McKinnell tells Oct. 17 conference call. Pfizer will copromote the BI agent, with launch expected in 2002 or 2003. BI's Columbus, Ohio facility "was to come on stream for production in 2005," McKinnell noted. The plant was the subject of an FDA warning letter in July (1"The Pink Sheet" July 30, p. 10)...
More from Archive
More from Pink Sheet
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.